.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Argus Health
UBS
Accenture
US Army
Citi
QuintilesIMS
Novartis
McKinsey
Colorcon

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202366

« Back to Dashboard
NDA 202366 describes LANSOPRAZOLE, which is a drug marketed by Labs Liconsa, Natco Pharma Ltd, Sun Pharm Inds Ltd, Krka Tovarna Zdravil, Perrigo R And D, Dexcel Pharma, Wockhardt Ltd, Ani Pharms Inc, Sandoz, Teva Pharms, Kremers Urban Pharms, Ajanta Pharma Ltd, Mylan Pharms Inc, Zydus Hlthcare, Inventia Hlthcare, Dr Reddys Labs Ltd, Wockhardt Usa, Teva Pharms Usa, Rising Pharms Inc, and Sandoz Inc, and is included in twenty-six NDAs. It is available from eighty-two suppliers. Additional details are available on the LANSOPRAZOLE profile page.

The generic ingredient in LANSOPRAZOLE is amoxicillin; clarithromycin; lansoprazole. There are forty-four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the amoxicillin; clarithromycin; lansoprazole profile page.

Summary for 202366

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 202366

Mechanism of ActionProton Pump Inhibitors
Physiological EffectInhibition Gastric Acid Secretion

Suppliers and Packaging for NDA: 202366

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LANSOPRAZOLE
lansoprazole
CAPSULE, DELAYED REL PELLETS;ORAL 202366 ANDA AvPAK 50268-465 50268-465-15 50 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-465-15) > 1 CAPSULE, DELAYED RELEASE PELLETS in 1 BLISTER PACK (50268-465-11)
LANSOPRAZOLE
lansoprazole
CAPSULE, DELAYED REL PELLETS;ORAL 202366 ANDA AvPAK 50268-466 50268-466-15 50 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-466-15) > 1 CAPSULE, DELAYED RELEASE PELLETS in 1 BLISTER PACK (50268-466-11)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED REL PELLETS;ORALStrength15MG
Approval Date:Aug 19, 2013TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED REL PELLETS;ORALStrength30MG
Approval Date:Aug 19, 2013TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Merck
McKinsey
US Army
Express Scripts
Mallinckrodt
Covington
Moodys
Citi
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot